Curium, a world leader in nuclear medicine, today announced that in Estonia, Finland, Latvia, and Sweden, PYLCLARI® is now ...

Curium introduces innovative 18F-PSMA PET radiopharmaceutical, Pylclari to treat prostate cancer in Estonia, Finland, Latvia, & Sweden: Paris, France Wednesday, January 29, 2025, ...

Portsmouth’s leading workspace, has announced a new lettings agreement with Curium - the world-leading nuclear medicine ...

Curium has remained an elusive element, with only seven crystal structures of curium molecular compounds reported from its ...

Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has entered into an agreement with Curium Pharma for the transfer of marketing and distribution rights ...

Scintimun is an internationally approved product [2] and has previously been manufactured and distributed by Curium Pharma through an out-license from Telix via the acquisition of TheraPharm in 2020 ...

Telix, a commercial-stage biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic (‘theranostic’) radiopharmaceuticals, announces that it has entered ...